3Q25 results missed expectations; target price cut but Buy maintained

Overview

This report is Goldman Sachs' commentary on Pien Tze Huang's (600436.SS) 3Q25 results. The company released its 3Q25 results on October 17, 2025, with revenue and net profit both below Goldman Sachs' expectations, mainly due to weak sales of core hepatopathy drugs, softer end-market demand, and resulting channel inventory pressure. The report therefore lowers 2025E-2027E forecasts and the 12-month target price, but maintains the Buy rating.

Core views

The core view is that near-term earnings pressure is clear, with 3Q25 revenue, net profit, and recurring net profit all declining significantly; weak hepatopathy drug sales were the main drag, and channel destocking weighed on quarterly performance; 4Q25 revenue may continue to decline YoY, but sequential recovery is more likely; over the medium to long term, Pien Tze Huang still has a strong brand, unique product attributes, and a deep moat, and Goldman Sachs expects valuation upside after growth recovers.

Analysis framework

The report analyzes actual results versus Goldman Sachs forecasts, core business sales trends, channel inventory judgment, margin and expense ratio analysis, forecast revisions, and a P/E-based target price methodology. It also incorporates end-market sales charts, a 2025E-2027E forecast revision table, and Goldman Sachs Factor Profile disclosure to explain growth, financial returns, valuation multiples, and integrated factors.

Methodology notes

• Valuation methodology12-month P/E target price

  Derives a 12-month target price of Rmb230 based on 50x PER.

  Goldman Sachs maintains a Buy rating on Pien Tze Huang, with the target price based on a 12-month PER methodology using a 50x P/E multiple. The target price was lowered from the previous Rmb270 to Rmb230.

• Earnings forecast revision2025E-2027E forecast adjustments

  Lowers revenue, net profit, and EPS forecasts for the next three years based on 3Q25 results missing expectations and sales pressure.

  The 2025E revenue forecast was cut from Rmb10,672mn to Rmb9,636mn, 2026E from Rmb11,541mn to Rmb10,379mn, and 2027E from Rmb12,842mn to Rmb11,480mn; EPS forecasts were also lowered.

• Factor frameworkGoldman Sachs Factor Profile

  Compares stock attributes versus the market and peers using growth, financial returns, valuation multiples, and integrated indicators.

  Growth is based on forward sales, EBITDA, and EPS growth; Financial Returns are based on ROE, ROCE, and CROCI; Multiple is based on valuation metrics such as P/E, P/B, P/D, EV/EBITDA, and EV/FCF; Integrated combines growth, financial returns, and inverse valuation multiples.

• M&A scoringM&A Rank

  Assesses the likelihood of being acquired on a scale of 1 to 3, with 3 indicating a lower probability.

  The chart shows Pien Tze Huang's M&A Rank at 3, indicating that Goldman Sachs believes it has a relatively low probability of becoming an acquisition target, usually with no material impact on the target price.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• 600436.SS

  Core covered company

  Strengths

  Pien Tze Huang has strong brand equity and unique traditional Chinese medicine product attributes. Its core eponymous product accounted for 49% of total revenue in 2024, and Goldman Sachs believes the company has a deep moat, with support for long-term gross margin and EBIT margin.

  Weaknesses

  3Q25 revenue and net profit were below expectations, core hepatopathy drug revenue fell 40% YoY, the selling and administrative expense ratio was higher than expected, and near-term revenue may continue to decline YoY in 4Q25.

  Comparison

  The report evaluates Pien Tze Huang's rating within Goldman Sachs' coverage universe of Chinese pharma, biotech, and medtech peers, and maintains a Buy rating.

  Risks

  Brand damage, new products and investment returns below expectations, sales volume after price hikes below expectations, discretionary consumption demand weaker than expected, channel restructuring results below expectations, cost inflation and raw material safety, ESG risks, and uncertainty around the CDI investigation.

• China Pharma, Biotech & Medtech

  Industry comparison universe

  Strengths

  Pharma consumption and traditional Chinese medicine brand assets can provide a long-term demand foundation for high-quality companies.

  Weaknesses

  Peer valuation, growth, and financial returns need to be dynamically compared in combination with end-market demand, channel inventory, and the policy environment.

  Comparison

  Goldman Sachs discloses Pien Tze Huang's rating relative to multiple Chinese pharma, biotech, and medtech companies under its coverage.

  Risks

  Industry demand volatility, policy and regulatory changes, channel adjustments, raw material costs, and intensifying competition may all affect sector valuation.

Key data

• 3Q25 revenueRmb2,064mn, YoY -26%Below Goldman Sachs' expectation of Rmb2,881mn.
• 3Q25 net profitRmb687mn, YoY -29%Below Goldman Sachs' expectation of Rmb922mn.
• 3Q25 recurring net profitRmb438mn, YoY -55%The difference versus reported net profit mainly came from Rmb250mn in gains from the disposal of financial assets.
• 3Q25 core hepatopathy drug revenueYoY -40%The report believes weak end-market sales and channel inventory accumulation were the main reasons.
• 3Q25 gross margin35.1%Slightly improved from 33.9% in 2Q25.
• 3Q25 selling and administrative expense ratio11.7%Higher than Goldman Sachs' expectation of 5.6%.
• 12-month target priceRmb230Cut from the previous Rmb270, based on 50x PER.
• Current share priceRmb196.34As of the close on October 17, 2025.
• Implied upside17.1%Based on the target price versus current price disclosed in the chart.
• 2025E revenue forecastRmb9,636mnDown 9.7% from the old forecast of Rmb10,672mn.
• 2026E revenue forecastRmb10,379mnDown 10.1% from the old forecast of Rmb11,541mn.
• 2027E revenue forecastRmb11,480mnDown 10.6% from the old forecast of Rmb12,842mn.
• 2025E EPSRmb4.25Down 10.5% from the old forecast of Rmb4.75.
• 2027E P/E32.6xThe chart shows the valuation multiple gradually declining from 46.2x in 2025E.

Impact & implications

The implication of the report for Pien Tze Huang is that near-term earnings and revenue expectations have been revised down, and the market needs to digest the impact of weak end-market sales of core products, channel destocking, and expense ratios above expectations; however, the Buy rating shows Goldman Sachs still believes brand barriers, product scarcity, long-term demand, and subsequent growth recovery can support valuation upside. For investment judgment, the key factors to verify next are whether end-market sales stabilize, whether channel inventory declines, and whether earnings recovery in 2026-2027 is realized.

Risks

• Unexpected events negatively affecting brand equity.
• New products and investment returns below expectations.
• Sales volume after price hikes weaker than expected.
• Willingness to spend on discretionary consumption lower than expected.
• Strategic channel restructuring results below expectations.
• Cost inflation and raw material safety risks.
• Unexpected ESG risks.
• Uncertainty in the ongoing CDI investigation.
• Continued weakness in end-market sales may cause the channel destocking cycle to last longer than expected.
• Expense ratios above expectations may further pressure margins.

What to watch

• Whether 4Q25 revenue continues to decline YoY, and whether the scale of sequential recovery materializes.
• Whether end-market sales of hepatopathy drugs stabilize from the weak state seen in the second half of 2025.
• Progress in channel inventory digestion and whether distributor operating pressure eases.
• Whether the selling and administrative expense ratio falls back closer to expected levels.
• Whether 2025E-2027E revenue, net profit, and EPS forecasts need further adjustment after the downward revisions.
• Sales volume performance after price hikes and demand resilience of core products.
• Whether there are new negative developments in the CDI investigation and ESG-related events.
• Whether valuation can regain support as earnings recover in 2026-2027.